603882 金域医学
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入5,618,852-10.95%8,539,62815,476,07511,943,2248,243,764
减:营业总成本5,117,589-8.22%7,635,23111,942,2609,158,1166,429,374
    其中:营业成本3,643,596-7.69%5,424,5368,801,5756,295,0184,395,136
               财务费用(969)-15.22%(1,054)(12,568)10,08817,552
               资产减值损失40-92.60%519232(519)(879)
公允价值变动收益------------
投资收益(5,123)-101.95%262,967(10,800)(7,295)(18,664)
    其中:对联营企业和合营企业的投资收益(5,494)-43.83%(9,815)(13,208)(8,848)(18,693)
营业利润110,211-82.84%759,7623,347,2342,776,7681,816,865
利润总额95,941-84.70%740,2893,320,7302,747,5571,810,474
减:所得税费用12,073-80.05%103,380475,721384,046237,041
净利润83,868-85.20%636,9092,845,0092,363,5121,573,432
减:非控股权益(9,971)6.44%(6,474)90,222143,87163,730
股东净利润93,839-83.71%643,3822,754,7872,219,6401,509,702

市场价值指针
每股收益 (元) *0.200-83.74%1.3805.9104.8003.290
每股派息 (元) *----0.8801.7801.2800.329
每股净资产 (元) *16.707-7.89%17.84018.47713.5408.242
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容